Incyte Corporation (INCY)

Incyte Corporation is a healthcare company focused on biotechnology and listed on NASDAQ as common stock. The company is engaged in the discovery, development, and commercialization of therapeutics across the United States, Europe, Canada, and Japan. Its marketed portfolio includes JAKAFI for myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG for certain leukemias; MONJUVI/MINJUVI for diffuse large B-cell lymphoma and follicular lymphoma; NIKTIMVO for chronic graft-versus-host disease; PEMAZYRE for selected cancers; and ZYNYZ for metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte also has clinical-stage programs in oncology and immunology, including candidates for ovarian cancer, solid tumors, and myeloproliferative neoplasms, as well as ruxolitinib cream and povorcitinib in immune-mediated and dermatologic indications. The company works with partners including Novartis, Lilly, and Syndax and sells products through specialty and retail pharmacies, hospital pharmacies, and distributors. Founded in 1991 and headquartered in Wilmington, Delaware, it was previously known as Incyte Genomics Inc.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.